Literature DB >> 23377623

Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference.

Shan-Fu Yu1, Tsong-Shing Yang, Wen-Chan Chiu, Chung-Yuan Hsu, Ching-Lan Chou, Yu-Jih Su, Han-Ming Lai, Ying-Chou Chen, Chung-Jen Chen, Tien-Tsai Cheng.   

Abstract

Adherence to anti-osteoporotic regimens gradually decreases over time. We hypothesized that the determinants of non-compliance or non-persistence at different times vary and identified these differences. We used an outpatient database to retrieve information on anti-osteoporotic medications prescribed by a medical centre in southern Taiwan during 2001-2007. Compliance was defined as a medication possession ratio (MPR) ≥80 %. Persistence was determined as continuous use, allowing for a refill gap of 30 days. A multivariate Cox regression model evaluated potential predictors of non-adherence. A total of 3589 patients were included. In the multivariate analyses, non-compliance for both year 1 and year 2 was more likely in patients with non-vertebral non-hip fractures, respiratory disorders, prescription of the first anti-osteoporotic regimen by an orthopedist; and less likely in patients with follow-up bone densitometry and switched regimens. Risks for non-persistence at year 1 and year 2 were generally similar to those for non-compliance; insurance coverage and malignancy were associated with a lower risk of non-persistence at year 1 and year 2, respectively. In the subgroup with an MPR ≥80 % at year 1, an index prescription by an orthopedist was the only independent predictor of non-compliance and non-persistence at year 2. In conclusion, the positive or negative determinants of non-adherence were different at year 1 and year 2, which indicated that clinicians might deliver effective interventions to improve adherence via different precautions annually. This study also provided evidence that physician specialty had a significant effect on adherence to osteoporosis care.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23377623     DOI: 10.1007/s00774-013-0424-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  33 in total

1.  Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study.

Authors:  Shan-Fu Yu; Ching-Lan Chou; Han-Ming Lai; Ying-Chou Chen; Chun-Kai Chiu; Ming-Chun Kuo; Yu-Jih Su; Chung-Jen Chen; Tien-Tsai Cheng
Journal:  Int J Rheum Dis       Date:  2012-02-13       Impact factor: 2.454

2.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

3.  Adherence to osteoporosis medications amongst Singaporean patients.

Authors:  M H H Cheen; M C Kong; R F Zhang; F M H Tee; M Chandran
Journal:  Osteoporos Int       Date:  2011-04-19       Impact factor: 4.507

Review 4.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

5.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

6.  Compliance with drug therapies for the treatment and prevention of osteoporosis.

Authors:  Jeffrey S McCombs; Patrick Thiebaud; Connie McLaughlin-Miley; Jinhai Shi
Journal:  Maturitas       Date:  2004-07-15       Impact factor: 4.342

7.  In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines.

Authors:  Sara L Thier; Kristina S Yu-Isenberg; Brian F Leas; C Ron Cantrell; Sandra DeBussey; Neil I Goldfarb; David B Nash
Journal:  Manag Care       Date:  2008-02

8.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

9.  Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women.

Authors:  Elaine Lau; Alexandra Papaioannou; Lisa Dolovich; Jonathan Adachi; Anna M Sawka; Sheri Burns; Kalpana Nair; Anjali Pathak
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

Review 10.  Non-hip peripheral osteoporotic fractures: epidemiology and significance.

Authors:  Mirko Korsić; Simeon Grazio
Journal:  Arh Hig Rada Toksikol       Date:  2008-03       Impact factor: 1.948

View more
  8 in total

Review 1.  A systematic review of factors affecting medication adherence among patients with osteoporosis.

Authors:  C T Yeam; S Chia; H C C Tan; Y H Kwan; W Fong; J J B Seng
Journal:  Osteoporos Int       Date:  2018-11-12       Impact factor: 4.507

Review 2.  Improving drug adherence in osteoporosis: an update on more recent studies.

Authors:  Ayesha Jaleel; Kenneth G Saag; Maria I Danila
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-07-10       Impact factor: 5.346

3.  Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.

Authors:  Chung-Yuan Hsu; Wen-Chan Chiu; Jia-Feng Chen; Ching-Lan Chou; Yu-Jih Su; Shan-Fu Yu; Tien-Tsai Cheng
Journal:  J Bone Miner Metab       Date:  2014-09-21       Impact factor: 2.626

4.  Fucoidan promotes osteoblast differentiation via JNK- and ERK-dependent BMP2-Smad 1/5/8 signaling in human mesenchymal stem cells.

Authors:  Beom Su Kim; Hyo-Jin Kang; Ji-Yun Park; Jun Lee
Journal:  Exp Mol Med       Date:  2015-01-09       Impact factor: 8.718

5.  Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.

Authors:  D-C Chan; C H-C Chang; L-C Lim; A J M Brnabic; J-Y Tsauo; R Burge; F-Y Hsiao; L Jin; S Gürbüz; R-S Yang
Journal:  Osteoporos Int       Date:  2016-05-12       Impact factor: 4.507

6.  The Growth Proliferation, Apoptotic Prevention, and Differentiation Induction of the Gelatin Hydrolysates from Three Sources to Human Fetal Osteoblasts (hFOB 1.19 Cells).

Authors:  Ming Lu; Xin-Huai Zhao
Journal:  Molecules       Date:  2018-05-28       Impact factor: 4.411

7.  Preparation, characterization, and osteogenic activity mechanism of casein phosphopeptide-calcium chelate.

Authors:  Wen Huang; Linhui Lao; Yuliang Deng; Ziwei Li; Wanwen Liao; Shan Duan; Suyao Xiao; Yong Cao; Jianyin Miao
Journal:  Front Nutr       Date:  2022-08-02

8.  Effect of Collagen Hydrolysates from Silver Carp Skin (Hypophthalmichthys molitrix) on Osteoporosis in Chronologically Aged Mice: Increasing Bone Remodeling.

Authors:  Ling Zhang; Siqi Zhang; Hongdong Song; Bo Li
Journal:  Nutrients       Date:  2018-10-04       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.